HKU Scholars Hub: Browsing DSpace

Browsing by Author Kudo, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 9 to 20 of 20 < previous

	Title	Author(s)	Issue Date	Views
	Liver cancer working group report Journal:Japanese Journal of Clinical Oncology	Kudo, M Han, KH Kokudo, N Cheng, AL Choi, BI Furuse, J Izumi, N Park, JW Poon, RT Sakamoto, M	2010	161
	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Journal:Lancet	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Kudo, M Hsu, C Kim, TY Choo, SP Trojan, J Welling, TH Meyer, T Kang, YK Yeo, W Chopra, A Anderson, J Dela Cruz, C Lang, L Neely, J Tang, H Dastani, HB Melero, I	2017	151
	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial Journal:Liver Cancer	Kudo, M Lim, HY Cheng, AL Chao, Y Yau, TCC Ogasawara, S Kurosaki, M Morimoto, N Ohkawa, K Yamashita, T Lee, KH Chen, E Siegel, AB Ryoo, BY	2020	38
	Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial Journal:Journal of Clinical Oncology	Finn, RS Ryoo, B-Y Merle, P Kudo, M Bouattour, M Lim, HY Breder, V Edeline, J Chao, Y Ogasawara, S Yau, T Garrido, M Chan, SL Knox, J Daniele, B Ebbinghaus, SW Chen, E Siegel, AB Zhu, AX Cheng, A-L The KEYNOTE-240 investigators	2020	95
	Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study Journal:Clinical Cancer Research	Finn, RS Kudo, M Cheng, AL Wyrwicz, L Ngan, RKC Blanc, JF Baron, AD Vogel, A Ikeda, M Piscaglia, F Han, KH Qin, S Minoshima, Y Kanekiyo, M Ren, M Dairiki, R Tamai, T Dutcus, CE Ikezawa, H Funahashi, Y Evans, TRJ	2021	14
	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study Journal:European Journal of Cancer	Chau, I Peck-Radosavljevic, M Borg, C Malfertheiner, P Seitz, JF Park, JO Ryoo, BY Yen, CJ Kudo, M Poon, RTP Pastorelli, D Blanc, JF Chung, HC Baron, AD Okusaka, T Bowman, L Cui, ZL Girvan, AC Abada, PB Yang, L Zhu, AX	2017	54
	Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma Journal:Annals of Oncology	Kang, YK Yau, TCC Park, JW Lim, HY Lee, TY Obi, S Chan, SL Qin, S Kim, RD Casey, M Chen, C Bhattacharyya, H Williams, JA Valota, O Chakrabarti, D Kudo, M	2015	51
	Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma Journal:Journal of Hepatology	Abou-Alfa, GK Puig, O Daniele, B Kudo, M Merle, P Park, JW Ross, P Peron, JM Ebert, O Chan, S Poon, RTP Colombo, M Okusaka, T Ryoo, BY Minguez, B Tanaka, T Ohtomo, T Ukrainskyj, S Boisserie, F Rutman, O Chen, YC Xu, C Shochat, E Jukofsky, L Reis, B Chen, G Di Laurenzio, L Lee, R Yen, CJ	2016	74
	A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results Proceeding/Conference:Annual Conference of the International Liver Cancer Association, ILCA 2013	Kudo, M Finn, R Poon, RTP Blanc, JF Han, G Yan, L Yang, J Lu, L Tak, WY XU, X Lee, JH Lin, SM Wu, C Tanwandee, T Shao, G Walters, L Dela Cruz, C Poulart, V Wang, JH	2013	42
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	74
	Safety and Antitumor Activity of Nivolumab (Nivo) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC): Interim Analysis of Dose-Expansion Cohorts from the Phase 1/2 CheckMate-040 Study Proceeding/Conference:Liver Cancer	Sangro, B Melero, I Yau, TCC Hsu, C Kudo, M Crocenzi, TS Kim, TY Choo, SP Trojan, J Meyer, T Kang, YK Anderson, J dela Cruz, C Lang, L Neely, J El-Khoueiry, AB	2016	151
	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study Journal:Journal of Clinical Oncology	Kelley, RK Sangro, B Harris, W Ikeda, M Okusaka, T Kang, YK Qin, S Tai, DWM Lim, HY Yau, T Yong, WP Cheng, AL Gasbarrini, A Damian, S Bruix, J Borad, M Bendell, J Kim, TY Standifer, N He, P Makowsky, M Negro, A Kudo, M Abou-Alfa, GK	2021	23

Showing results 9 to 20 of 20 < previous